@ARTICLE{
author={Mateos Maria-Victoria,Szarejko Monika,Bila Jelena S,Schjesvold Fredrik,Spicka Ivan,Maisnar Vladimir,Jurczyszyn Artur,Grudeva-Popova Zhanet,Hajek Roman,Usenko Hanna,Thuresson Marcus,Norin Stefan,Jarefors Sara,Richardson Paul,Pour Ludek},
year={2023},
title={Lighthouse: melflufen, daratumumab, and dexamethasone versus daratumumab in relapsed/refractory multiple myeloma refractory to an imid and a proteasome inhibitor or with ≥3 prior lines of therapy},
journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA},
volume={23},
number={},
pages={S200-S201},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Kropff M,Baylon H,Spicka Ivan,Hillengass J,Roback T,Salwender H,Hajek Roman,Liebisch P,Boskovic Darinka V,Goranov S,Zerbib R},
year={2009},
title={OPTIMUM Trial: Randomized Comparison of Thalidomide Versus Dexamethasone for Relapsed Myeloma},
journal={CLINICAL LYMPHOMA & MYELOMA},
volume={9},
number={},
pages={S64-S64},
document_type={Meeting Abstract},
}